<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs that can impair glucose tolerance or cause overt diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs that can impair glucose tolerance or cause overt diabetes mellitus</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drugs that can impair glucose tolerance or cause overt diabetes mellitus</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Category</td> <td class="subtitle1">Agents</td> <td class="subtitle1">Mechanism<sup>*</sup></td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Anti-infectives</strong></td> </tr> <tr> <td class="indent1">Fluoroquinolones</td> <td>Gatifloxacin<sup>¶</sup> (not available in United States), moxifloxacin</td> <td>Altered insulin secretion. Association with moxifloxacin is rare.</td> </tr> <tr> <td class="indent1">HIV antiretrovirals</td> <td> <p>Protease inhibitors</p> Nucleoside reverse transcriptase inhibitors (NRTIs)</td> <td>Increased peripheral insulin resistance. Part of antiretroviral-associated metabolic syndrome.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Other anti-infectives</td> <td>Pentamidine</td> <td>Altered pancreatic beta cell function. Following initial hypoglycemic effect, beta cell destruction can occur.</td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Antipsychotics</strong></td> </tr> <tr> <td class="indent1">First-generation</td> <td>Chlorpromazine<sup>¶</sup>, perphenazine, other phenothiazines</td> <td>Mechanism not established. Appears to involve increased insulin resistance and diminished insulin secretion.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Second-generation</td> <td>Clozapine<sup>¶</sup>, iloperidone, olanzapine<sup>¶</sup>, paliperidone, quetiapine, risperidone</td> <td>Mechanism not established. Appears to involve increased insulin resistance and diminished insulin secretion.</td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Cardiovascular</strong></td> </tr> <tr> <td class="indent1">Beta blockers</td> <td>Atenolol, metoprolol, <span class="nowrap_whitespace">propranolol<sup>[1]</sup></span></td> <td> <p>Decreased insulin sensitivity (moderate effect).</p> <p>Carvedilol does not appear to impair glucose tolerance.</p> Refer to UpToDate topic on treatment of hypertension in patients with diabetes mellitus.</td> </tr> <tr> <td class="indent1">Hypolipidemic</td> <td>Niacin (nicotinic acid)<sup>¶</sup>, statins</td> <td> <p>Niacin – Altered hepatic glucose metabolism, probably greater with extended-release form.</p> Statins – Evidence of impaired glucose tolerance due to statins is conflicting, and overall risk appears low.</td> </tr> <tr> <td class="indent1">Thiazide diuretics</td> <td>Hydrochlorothiazide, chlorthalidone, chlorothiazide, indapamide</td> <td> <p>Reduced total-body potassium, decreased insulin secretion, and increased insulin <span class="nowrap_whitespace">resistance<sup>[2]</sup>.</span></p> <p>Infrequent with low dosages (ie, hydrochlorothiazide ≤25 mg or equivalent).</p> Potassium supplementation may decrease thiazide-associated glucose intolerance.</td> </tr> <tr> <td class="indent1">Vasodilators</td> <td>Diazoxide</td> <td>Reduced insulin secretion and sensitivity, increased hepatic glucose production.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Vasopressors</td> <td>Epinephrine<sup>¶</sup>, <span class="nowrap_white-space">norepinephrine<sup>[3]</sup></span></td> <td>Activation of glycogenolysis, increased hepatic gluconeogenesis, stimulation of glucagon and cortisol, inhibition of insulin secretion.</td> </tr> <tr class="divider_bottom"> <td><strong>Gonadotropin-releasing hormone agonists</strong></td> <td>Class effect in males receiving androgen deprivation therapy for metastatic prostate cancer</td> <td>Refer to UpToDate topic on side effects of androgen deprivation therapy.</td> </tr> <tr class="divider_bottom"> <td> <p><strong>Glucocorticoids, systemic</strong><sup>*</sup></p> <p class="indent1">NOTE: Glucocorticoids are a particularly common cause of clinically significant drug-induced hyperglycemia</p> </td> <td>Class effect</td> <td> <p>Multifactorial, including increased hepatic glucose production, increased insulin resistance, increased expression of peroxisome proliferator activated gamma receptors (PPAR-gamma).</p> Refer to UpToDate topic on major side effects of systemic glucocorticoids.</td> </tr> <tr class="divider_bottom"> <td><strong>Hormones, growth</strong></td> <td>Somatropin, tesamorelin</td> <td> <p>Increased counterregulatory responses.</p> Refer to UpToDate topics on treatment of growth hormone deficiency and treatment of HIV-associated lipodystrophy.</td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Immune checkpoint inhibitors</strong></td> </tr> <tr> <td class="indent1">Programmed cell death receptor 1 (PD-1) inhibitors</td> <td>Nivolumab, pemprolizumab, cemiplimab</td> <td class="divider_bottom" rowspan="3">PD-1 and PD-L1 inhibitors overcome immune suppression of cytotoxic T cells in the tumor milieu; CTLA-4 inhibitors overcome immune suppression of cytotoxic T cells in secondary lymphoid tissues. Immune checkpoint inhibitors promote activation of cytotoxic T cells that act "off target" to attack and destroy islet cells.</td> </tr> <tr> <td class="indent1">Programmed cell death ligand 1 (PD-L1) inhibitors</td> <td>Atezolizumab, avelumab, durvalumab</td> </tr> <tr class="divider_bottom"> <td class="indent1">Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors</td> <td>Iipilimumab, tremelimumab</td> </tr> <tr> <td><strong>Immunosuppressants</strong></td> <td>Cyclosporine (cyclosporin), sirolimus, tacrolimus</td> <td> <p>Decreased insulin synthesis and release.</p> Refer to UpToDate topic on new-onset diabetes after transplant in kidney transplant recipients.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>* Degree or incidence of hyperglycemia is generally related to dose.</p>
¶ Among agents listed, these have been more frequently associated with hyperglycemia and/or diabetes mellitus.</div><div class="graphic_reference">Data from:
<ol>
<li>Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006; 99:431.</li>
<li>Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286:1945.</li>
<li>Thomas Z, Bandali F, McCowen K, Malhotra A. Drug-induced endocrine disorders in the intensive care unit. Crit Care Med 2010; 38:S219.</li>
</ol></div><div id="graphicVersion">Graphic 67257 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
